The downgrade by a notable analyst firm, Leerink Partners, from Outperform to Market Perform, coupled with a substantial decrease in the price target, is likely to negatively impact investor sentiment and the short-term stock price of CureVac. Such analyst actions often lead to immediate market reactions, as they may reflect changes in the company's outlook or market position.